CClinicalTrials.gg
CompletedNCT00046449Updated Jun 4, 2015

Prevention of Seasonal Affective Disorder

A Phase 3 interventional study of Investigational Seasonal Affective Disorder (SAD) Drug in Seasonal Affective Disorder (SAD), sponsored by GlaxoSmithKline. Completed at 54 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-04.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Placebo Controlled Study Evaluating The Effectivess Of Medication In Preventing Seasonal Affective Disorder

02

Conditions studied

  • Seasonal Affective Disorder (SAD)
03

In context

Mood Disorders

584 studies on the registry are indexed under Mood Disorders; 117 are open to participants now.

Browse Mood Disorders studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.

Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: (Patient must meet these criteria in order to be eligible for this study.)

  • Patient has a history of Major Depressive Disorder (MDD) with a seasonal pattern.

Exclusion Criteria: (Patient cannot meet these criteria in order to be eligible for this study.)

  • Patient has a current or past history of seizure disorder or brain injury.
  • Patient has a history or current diagnosis of anorexia nervousa or bulimia.
  • Patient has recurrent summer depression more frequently than winter depression.
  • Patient has primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), acute distress disorder, bipolar II disorder or other psychotic disorders.
  • Patient has initiated psychotherapy within the last 3 months.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double

Interventions

  • DrugInvestigational Seasonal Affective Disorder (SAD) Drug
06

Study locations

54 sites
  • Study Site
    Homer, Alaska 99603, United States
  • Study Site
    New Haven, Connecticut 06504-0605, United States
  • Study Site
    Newark, Delaware 19713, United States
  • Study Site
    Wilmington, Delaware 19808-1251, United States
  • Study Site
    Washington, District of Columbia 20016, United States
  • Study Site
    Washington, District of Columbia 20037, United States
  • Study Site
    Boise, Idaho 83704, United States
  • Study SIte
    Chicago, Illinois 60610, United States
  • Study Site
    Chicago, Illinois 60612, United States
  • Study Site
    Hoffman Estates, Illinois 60194, United States
  • Study Site
    Libertyville, Illinois 60048, United States
  • Study SIte
    Northfield, Illinois 60093, United States
  • Study Site
    Schaumburg, Illinois 60194, United States
  • Study SIte
    Greenwood, Indiana 46143, United States
  • Study Site
    Indianapolis, Indiana 45202, United States
  • Study Site
    Florence, Kentucky 41042, United States
  • Study Site
    Wellesley Hills, Massachusetts 02481, United States
  • Study Site
    Okemos, Michigan 48864, United States
  • Study Site
    Royal Oak, Michigan 48067, United States
  • Study Site
    Minneapolis, Minnesota 55454, United States
  • Study Site
    Moorestown, New Jersey 08057, United States
  • Study Site
    Piscataway, New Jersey 08854, United States
  • Study Site
    Amityville, New York 11701, United States
  • Study Site
    Lawrence, New York 11559, United States
  • Study Site
    New York, New York 10021, United States
  • Study Site
    Olean, New York 14760, United States
  • Study Site
    Staten Island, New York 10305, United States
  • Study Site
    Williamsville, New York 14221, United States
  • Study Site
    Cincinnati, Ohio 45219, United States
  • Study Site
    Cleveland, Ohio 44106, United States
  • Study Site
    Cleveland, Ohio 44121, United States
  • Study Site
    Independence, Ohio 44131, United States
  • Study Site
    Lyndhurst, Ohio 44124, United States
  • Study Site
    Toledo, Ohio 43623, United States
  • Study Site
    Eugene, Oregon 97401, United States
  • Study Site
    Portland, Oregon 97201, United States
  • Study Site
    Portland, Oregon 97209, United States
  • Study Site
    Salem, Oregon 97309, United States
  • Study Site
    Allentown, Pennsylvania 18104, United States
  • Study Site
    Philadelphia, Pennsylvania 19106, United States
  • Study Site
    Philadelphia, Pennsylvania 19107, United States
  • Study Site
    Lincoln, Rhode Island 02865-4208, United States
  • Study Site
    Seattle, Washington 98104, United States
  • Study Site
    Madison, Wisconsin 53719, United States
  • Study Site
    Middleton, Wisconsin 53562, United States
  • Study Site
    Milwaukee, Wisconsin 53226, United States
  • Study Site
    West Allis, Wisconsin 53227, United States
  • Study Site
    Edmonton, Alberta T6G 2C8, Canada
  • Study Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Study Site
    Miramichi, New Brunswick E1V 3G5, Canada
  • Study Site
    Sydney, Nova Scotia B1S 2E8, Canada
  • Study Site
    Markham, Ontario L6B 1A1, Canada
  • Study Site
    Mississauga, Ontario L4W 1N2, Canada
  • Study Site
    Hull, Quebec J9A 1K7, Canada
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00046449
Lead sponsor
GlaxoSmithKline
First posted
Oct 2, 2002
Start date
Sep 2002
Primary completion
Jun 2003
Completion
Jun 2003
Last update
Jun 4, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion